EBV-Positive DLBCL, Nos: Clinical Trials

7 trials for EBV-Positive DLBCL, Nos, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 unknown, 1 active not recruiting, 1 terminated. 7 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Unknown 5, Active not recruiting 1, Terminated 1
Phase 13Unknown 3

Follow EBV-Positive DLBCL, Nos: new trials by email Literature Review of EBV-Positive DLBCL, Nos trials Research Report on EBV-Positive DLBCL, Nos

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma
Phase 2Active not recruitingPatrick C. Johnson, MD282023-03-012026-01-29
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Nanatinostat in combination with valganciclovir - Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
Phase 2TerminatedViracta Therapeutics, Inc.1022021-05-282025-07-28
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang302021-03-312021-03-15
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
Zanubrutinib, Tislelizumab - Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos
Phase 2UnknownRuijin Hospital402021-01-012021-03-30
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang332020-07-232021-03-15
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang1402020-04-242022-04-14
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
Sintilimab, Rituximab, Cyclophosphamide - EBV-Positive DLBCL, Nos
Phase 2UnknownThe First Affiliated Hospital with Nanjing Medical University552019-01-012019-11-29

Narrower conditions

Pyloric Stenosis, Hypertrophic (7)  ·  Lymphoma, Large B-Cell, Diffuse (3)  ·  Recurrence (2)  ·  Epstein-Barr Virus Infections (1)  ·  Lymphoma, B-Cell (1)

Broader conditions

Digestive System Diseases (7)  ·  Gastric Outlet Obstruction (7)  ·  Gastrointestinal Diseases (7)  ·  Pyloric Stenosis (7)  ·  Stomach Diseases (7)  ·  Hemic and Lymphatic Diseases (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Lymphatic Diseases (3)  ·  Lymphoma (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Disease Attributes (2)

Interventions

Cyclophosphamide (2)  ·  Rituximab (2)  ·  tislelizumab (2)  ·  Doxorubicin (1)  ·  Lenalidomide (1)  ·  Prednisolone (1)  ·  R-CHOP protocol (1)  ·  Valganciclovir (1)  ·  Vincristine (1)  ·  acalabrutinib (1)  ·  apatinib (1)  ·  camrelizumab (1)  ·  fludarabine (1)  ·  sintilimab (1)  ·  spartalizumab (1)

Sponsors

Huiqiang Huang (3)  ·  Patrick C. Johnson, MD (1)  ·  Ruijin Hospital (1)  ·  The First Affiliated Hospital with Nanjing Medical University (1)  ·  Viracta Therapeutics, Inc. (1)

Countries

China (5)  ·  United States (2)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Connor Johnson, MD (1)  ·  Darrel P Cohen, MD, PhD (1)  ·  Huiqiang Huang, Professor (1)  ·  Wei Xu, M.D., Ph.D. (1)  ·  Weili Zhao, PhD, MD (1)

Results publications

PMID 37530631